Hemostemix Inc. (CVE:HEM – Get Free Report)’s stock price passed below its fifty day moving average during trading on Thursday . The stock has a fifty day moving average of C$0.08 and traded as low as C$0.07. Hemostemix shares last traded at C$0.07, with a volume of 8,000 shares traded.
Hemostemix Stock Down 12.5 %
The stock has a market capitalization of C$6.10 million, a P/E ratio of -3.50 and a beta of 0.20. The firm has a 50-day moving average of C$0.08 and a 200 day moving average of C$0.07.
Hemostemix Company Profile
Hemostemix Inc, a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia.
Further Reading
- Five stocks we like better than Hemostemix
- What is the Hang Seng index?
- Buffett Takes the Bait; Berkshire Buys More Oxy in December
- Industrial Products Stocks Investing
- Top 3 ETFs to Hedge Against Inflation in 2025
- How to Calculate Retirement Income: MarketBeat’s Calculator
- These 3 Chip Stock Kings Are Still Buys for 2025
Receive News & Ratings for Hemostemix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemostemix and related companies with MarketBeat.com's FREE daily email newsletter.
